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ABSTRACT
Dysfunctional apoptotic machinery is a hallmark feature of chronic lymphocytic 
leukemia (CLL). Accordingly, targeting apoptosis regulators has been proven a 
rational approach for CLL treatment. We show that CLL lymphocytes express high 
levels of XIAP, cIAP1, and cIAP2 compared to normal lymphocytes. Smac mimetic, 
Smac066, designed to bind to BIR3-domain of IAPs, induce apoptosis in primary 
CLL cells (n=71; p<0.0001), irrespective of prognostic markers. Apoptosis was 
mediated by diminished levels of IAPs (XIAP-p=0.02; cIAP-p<0.0001) and increased 
activation of caspases-8,-9,-3. The caspase-cleavage was in direct association 
with the levels of apoptosis (r2=0.8 for caspases-8,-9,-3). Correlative analysis 
revealed a direct relationship between reduction in IAPs and degree of apoptosis 
(r2=0.6 (XIAP); 0.5 (cIAP2)). There was a strong association between apoptosis, 
IAP-degradation, and concurrent caspase-activation. Pan-caspase inhibitor Z-Vad-
fmk reversed the degradation of Mcl-1, but not IAPs suggesting that smac066 is 
selective to IAPs, however, Mcl-1 degradation is through caspase-mediated cleavage. 
Immunoprecipitation experiments revealed physical interaction between caspase-3 
and XIAP that was disrupted by smac066. Importantly, XIAP and cIAP2 were markedly 
induced in bone-marrow and lymph-node microenvironments, providing a basis for 
IAP antagonists as anti-tumor agents in CLL. Smac066 synergized with ABT-737, 
revealing a mechanistic rationale to jointly target BH3 and BIR3 domains.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most 
common form of adult leukemia in the Western world. The 
fundamental hallmark feature of CLL biology is defective 
apoptosis, a major target for activation. Resistance to 
apoptosis in CLL stems primarily from high levels of 
Bcl-2-family anti-apoptotic proteins [1] and inhibitor-
of-apoptosis proteins (IAPs) [2, 3], [4]. IAPs inhibit 
apoptosis by neutralizing the activities of caspases, a 
family of proteases that act in concert to execute apoptosis 
or programmed cell death [4, 5]. Eight IAPs have been 
identified. The protein structures of IAPs contain one or 
more baculovirus IAP repeat (BIR) domains, which are 
essential for the interaction of IAPs with caspases. The 
carboxyl end consists of a RING zinc finger domain 
with E3 ubiquitin ligase activity, which facilitates auto-
degradation of IAPs. IAPs, such as cellular IAP1 (cIAP1) 
and cIAP2, also contain a caspase-associated recruitment 
domain (CARD) between the BIR3 domain and the 
C-terminal RING domain [6]. Previous studies reported 
that while the BIR2 domain or the linker between BIR1 
and BIR2 in X-linked IAP (XIAP) interacts with the 
tetrapeptide binding motif of cellular caspases-3 and 
-7, the BIR3 domain primarily targets the pro-apoptotic 
activity of caspase-9 [7, 8]. 
The endogenous apoptosis-inducing factor Smac 
(second mitochondria-derived activator of caspases; also 
known as direct inhibitor of apoptosis protein-binding 
protein with low pI (DIABLO)) is a mitochondrial protein 
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that is released into the cytosol in response to apoptotic 
stimuli [9]. Smac functions as an endogenous antagonist of 
IAP family proteins, XIAP, cIAP1, and cIAP2 that inhibit 
apoptosis by sequestering caspases. Mechanistically, the 
wild-type Smac protein (residues 1–184) forms a dimer in 
solution and interacts with both BIR2 and BIR3 domains 
of XIAP and or the linker region of XIAP. Such a dynamic 
and competitive protein-protein interaction between 
Smac and XIAP cooperatively neutralizes the inhibition 
of caspases [10]. 
The therapeutic strategy of restoring or reactivating 
apoptosis was initially investigated using a synthetic Smac 
peptide that mimic the tetrapeptide N-terminal Smac 
sequence (AVPI; Ala-Val-Pro-Ile) with higher binding 
affinity to IAPs. Crystal structure studies indicated that 
the IAP-binding tetrapeptide motif of Smac and that of 
caspase-9 (Ala-Thr-Pro-Phe) bind to the same conserved 
surface groove in the BIR3 domain of XIAP [11]. This 
competitive binding of Smac to XIAP leads to pro-
apoptotic mechanism, whereas binding of caspases to 
XIAP results in pro-survival contrivance, providing a 
mechanistic rationale for developing Smac mimetics as 
anti-cancer agents for the concurrent reversal of IAP-
mediated inhibition of caspases [12-14]. 
Several strategies have been put forth for targeting 
IAPs; some involve short Smac-based peptides, small-
molecule mimetics, and/or antisense IAP oligonucleotides 
[15-17]. A Smac-based peptide containing the AVPI 
sequence was shown to bind to BIR3 and BIR2 domains 
of recombinant XIAP with kd values of 0.4–0.7 µM and 
6-9 µM, respectively [18]. However, because Smac-
based peptides are not cell permeable, non-peptide small-
molecule mimetics are synthesized as an alternative. 
Monovalent small-molecule mimetics that could target 
either the XIAP BIR3 domain to inhibit the binding of 
XIAP to caspase-9 [19] or the BIR2 domain, to block the 
interaction of XIAP with caspase-3/-7 [20] are designed. 
More advanced bivalent small molecules that can bind to 
both the BIR2 and the BIR3 domains are also synthesized. 
These bivalent molecules are particularly efficient 
and more potent antagonists than the corresponding 
monovalent Smac mimetics [20-22]. Therefore, concurrent 
targeting of the BIR2 and BIR3 domains in XIAP is a 
highly attractive strategy to antagonize IAPs and promote 
apoptosis in cancer cells. However, bivalent mimetics 
have a higher molecular weight and may require parenteral 
administration [23].
In this study, we investigated reactivation of 
apoptosis in CLL with smac066, a small-molecule Smac 
mimetic synthesized at the University of Milan - Center 
for Biomolecular Interdisciplinary Studies and Industrial 
Applications (CISI Scrl). This monomer was shown to 
have high affinity for the BIR3 domain of XIAP, cIAP1, 
and cIAP2 (IC50, 110 nM), [24-26] lower-nanomolar 
potency in MDA-MB231 cells, and low-micromolar 
potency in HL-60 and PC-3 cells [24]. The Smac 
mimetics investigated thus far have shown cytotoxicity 
only in combination with other chemotherapeutic drugs 
[27, 28] by sensitizing a broad range of tumor cells to 
tumor necrosis factor alpha (TNFα) and other death 
ligands particularly to TNF–related apoptosis–inducing 
ligand (TRAIL) [21]. Smac066 exhibited pro-apoptotic 
activity and induced apoptosis as a single agent in CLL. 
Apoptosis was mediated by diminished levels of IAPs 
and an increase in activation of caspases 8, 9, and 3. 
Immunoprecipitation experiments revealed that caspase-3 
and XIAP were in physical association with each other and 
smac066 was able to disrupt the interaction and promote 
caspase-3 activation. Importantly, XIAP and cIAP2 
were markedly induced in bone marrow and lymph node 
microenvironments; promoting a paradigm shift towards 
anti-apoptotic mechanisms. Finally, smac066 when 
combined with ABT-737 exhibited synergism implicating 
that targeting Bcl-2 family and IAP family proteins in 
parallel, could be a novel strategy to promote apoptosis 
in CLL. 
RESULTS
IAPs are expressed at high levels in CLL 
lymphocytes 
The endogenous levels of target proteins (IAPs) 
were compared between CLL lymphocytes and normal 
PBMCs. Lymphocytes obtained from CLL patients (first 9 
lanes; Figure 1A) and healthy donors (last 7 lanes; Figure 
1A) were lysed under identical experimental conditions 
and evaluated for IAPs. XIAP, cIAP1, and cIAP2 
proteins were higher in CLL lymphocytes than in normal 
lymphocytes (p=0.005, 0.0009, and 0.01, respectively; 
Figure 1B). Given that Smac is an endogenous pro-
apoptotic protein, one would expect it to be higher in 
normal PBMCs; however, no difference in expression was 
observed between two cohorts of samples. 
Single agent Smac066, sensitizes CLL lymphocytes 
to apoptosis 
Smac066 induced apoptosis in CLL cells with 
median IC50 concentrations of 8 µM (range 6-10 µM) at 
24 hr, 6 µM (range 3-15 µM) at 48 hr, and 6 µM (range 
4-9 µM) at 72 hr (Figure 2A; n=5). The heterogeneity in 
response to apoptosis (Figure 2B; n=69; p=0.0001) was 
analyzed in relation to CLL prognostic markers (Figure 
2C). Samples with 13q14 deletion were consistently 
sensitive to smac066 (n=18; p=0.0002). Samples with 
trisomy 12 were equally sensitive to smac066 (n=6; 
p=0.047). Of the samples with nodal sites and spleen, 
five samples were sensitive to apoptosis (p=0.01) but 
seven were resistant (p=0.586). Interestingly, two 
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subsets of 17p deletion samples, one, sensitive (n=5; 
p=0.008) and other resistant to apoptosis (n=4; p=0.65) 
were observed. Samples with 11q deletion and multiple 
prior treatments were invariably resistant to smac066; 
however, the sample size was low (n=3; Figure 2C). 
DiOC6 staining, an alternative method of measuring 
apoptosis that is more specific to outer mitochondrial 
membrane permeabilization, was performed in parallel for 
comparison. In general, the results obtained with annexin 
V/PI binding are in linear correlation with DiOC6 staining 
[29]. However, in this case, apoptosis measured by DiOC6 
staining was significantly higher than that measured by 
the annexin V/PI binding, particularly at the earlier time 
points (5-12 hr; Figure 2D). 
Down-regulation of IAPs with Smac066 
Given that IAPs are potential targets of smac066, 
we next investigated the downstream consequences of 
inhibition. With 5 µM smac066, there was a significant 
diminution in XIAP and cIAP2 levels (Figure 3A; 24 hr). 
When the same samples were tested for anti-apoptotic 
proteins Mcl-1 (Figure 3A; 24 hr), additional samples for 
Bcl-2, and Bcl-xL (Figure 3B), a reduction was observed 
for Mcl-1 but not for Bcl-2 or Bcl-xL. Additional samples 
analyzed (Figure 3C; n=8) demonstrated heterogeneity for 
degradation of IAPs and Mcl-1 (degradation correlated 
with sensitivity to smac066). Overall, there was a 
significant reduction in protein levels following smac066 
treatment (p=0.02 for XIAP, p<0.0001 for cIAP, p=0.008 
for Mcl-1) (Figure 3D-3F). Correlative analysis revealed 
a linear relationship between reduction in protein levels 
and degree of apoptosis, suggesting that reactivation of 
apoptosis by smac066 is associated with diminution in 
IAP levels (Figure 3G-3I; r2=0.6 for XIAP, r2 = 0.5 for 
cIAP, r2=0.5 for Mcl-1; n=8).
Activation of caspases with Smac066
Smac is an endogenous apoptosis-inducing factor, 
and its function is to neutralize the anti-apoptotic 
properties of IAPs, which sequester the pro-apoptotic 
caspases and impede their activation. On the basis 
of this concept, we investigated smac066-mediated 
apoptosis in relation to activation of caspase cascade. 
The lysates from same samples were evaluated for 
caspase activation (Figure 3J; n=8 for caspase-8 and -9 
and n=6 for caspase-3). Compared to untreated samples, 
smac066-treated samples demonstrated significantly 
greater cleavage of caspase-8 (cleaved fragment of 43 
KD), caspase-9 (leading to cleaved fragments of 37 and 
35 KD), and caspase-3 (Figure 3J). Importantly, the levels 
of cleaved fragments were in direct association with the 
levels of apoptosis in primary CLL cells, suggesting 
that smac066-induced apoptosis is a direct outcome of 
conversion of pro-caspases into active caspases (Figure 
3K-M; r2= 0.8 for caspase-8 (n=8), caspase-9 (n=8), and 
caspase-3 (n=6)).
Pan-caspase inhibitor, Z-Vad-fmk abrogates the 
smac066 mediated apoptosis
To further understand the mechanism of caspase 
activation in smac066-induced cell death, we tested if 
inhibition of caspases with pan-caspase inhibitor Z-Vad-
fmk would abrogate smac066-mediated apoptosis in CLL 
cells. Incubation with Z-Vad-fmk partially but significantly 
inhibited smac066-mediated apoptosis in CLL primary 
cells (Figure 4A; p=0.015; n=12). To further explore the 
mechanisms of IAP degradation and their association with 
caspase-mediated cleavage, protein levels of IAPs (Figure 
4B) and Bcl-2 family proteins (Figure 4C) were evaluated 
following smac066 treatment in the presence or absence of 
Figure 1: Comparison of expression levels of IAP proteins between CLL and normal lymphocytes. A. Lymphocytes from 
patients with CLL (n = 9) and PBMCs from healthy donors (n = 7) were pelleted, lysed and evaluated for XIAP, cIAP1, and cIAP2 by 
immunoblotting analysis. GAPDH was used as a loading control. B. The immunoblots were quantitated and normalized to GAPDH. The 
horizontal lines denote median values. NL = normal lymphocytes. 
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Z-Vad-fmk. Degradation of Mcl-1 was partially reversed 
by the addition of Z-Vad-Fmk, however, degradation of 
IAPs was not restored; suggesting that while IAPs are 
down-regulated through degradation mechanism, Mcl-1 
diminution is driven through caspase-mediated cleavage 
(Figure 4B and 4C).
Although Smac protein acts downstream of 
mitochondria, it is possible that a positive feedback loop 
mechanism ruptures the mitochondrial outer membrane 
potential and induces cytochrome c release and apoptosis, 
with subsequent involvement of Bax/Bak. To test this 
possibility, exponentially growing Bax/Bak wild-type 
or double-knockout mouse embryo fibroblasts were 
incubated with equivalent concentrations of smac066, and 
apoptosis was measured after 24 hr. The results showed 
that Bax/Bak are required for smac066-induced apoptosis, 
but not for growth inhibition (Figure 4D).
Smac066 dissociates the protein-protein 
interaction between IAPs and caspases
Mechanistic studies revealed that the BIR2 and 
BIR3 domains of IAPs sequester caspases and neutralize 
their pro-apoptotic function[30]. To investigate whether 
the apoptosis induced by smac066 in CLL primary cells 
is mediated by disruption of protein–protein interaction 
between XIAP and caspase-3, immuno-precipitation 
analyses were conducted (Figure 5). The first two lanes 
show results for whole-cell lysates (input) probed with 
respective antibodies. The next four lanes show results 
for lysates immunoprecipitated with none (first lane) IgG 
mouse (second lane), mouse XIAP (third lane) and mouse 
XIAP (fourth lane) antibody. “C” represents untreated 
control and “S” represents smac066 treated. Western 
blot for XIAP, cIAP2, and caspase-3 confirmed that the 
pull-down with XIAP antibody was efficient, as indicated 
by the presence of XIAP, but not cIAP2. The same blots 
Figure 2: Restoration of smac066-mediated apoptosis in CLL primary cells. A. CLL lymphocytes were incubated with serial 
concentrations of smac066 (0-100 µM; n = 5), and apoptosis was determined at 24, 48, and 72 hr by annexin V/PI binding assay. Fifty-
percent inhibitory concentrations for all time points were determined using GraphPad software. B. Additional samples were evaluated for 
cell death in a similar fashion (5 µM; 24 hr; n = 69). The given p value is derived from paired t-test analyzed using Graph Pad Prizm. C = 
untreated CLL. C. Cell viability in relation to prognostic markers for individual patient samples. The values are relative to untreated time 
matched control (100%). The given p-values are derived from paired t-test between treated and untreated sample, analyzed using Graph 
Pad Prizm. Horizontal lines represent median values. 13q14del = miR15 and -16a locus; t12 = samples with trisomy 12 (three copies of 
chromosome 12); 17pdel = samples with deletion of chromosome 17p, the locus of p53, a tumor suppressor gene; 11qdel = samples with 
deletion of chromosome 11q, which is the locus of the ATM gene; Rx = treatments; IgVH = immunoglobulin heavy chain. D. Comparison 
of smac066-mediated apoptosis in CLL primary cells between annexin V/PI binding assay (left panel) and DiOC6 staining (right panel). 
The horizontal lines denote mean ± SEM values.
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Figure 3: Degradation of IAPs and activation of caspases (8, 9, and 3) following smac066 treatment. A.-B. Primary CLL 
cells were untreated or treated with smac066 (S) (5 µM). A. IAPs (XIAP, cIAP1 and anti-apoptotic Mcl-1) B. cIAP1 and anti-apoptotic 
family Bcl-2, and Bcl-xL were evaluated by immunoblotting analysis. Pt = patient; C = untreated CLL; S = smac066. C. Additional samples 
were evaluated in a similar fashion (n = 8). The specific bands for XIAP and cIAP2 are indicated by arrows. Prognosis and percent viable 
cells determined by annexin V/PI binding assay for each sample is provided. The blots originated from the same gel (the membrane is 
either cut into different pieces according to kD of the protein or probed with two antibodies (XIAP and cIAP2) of different species (rabbit/
mouse) at the same time; this is technically feasible with LI-COR Odyssey infrared imager. D.-F. Quantitation of immunoblots (3C) for 
XIAP, cIAP2, and Mcl-1, normalized to GAPDH levels. G.-I. Correlation between percent viable cells and protein levels of XIAP, cIAP2, 
and Mcl-1 following 24-hr treatment with smac066 (5 µM; n = 8). The r2 on the correlation is obtained through linear regression analysis. J. 
Primary CLL cells were untreated or treated with smac066 (S) (5 µM) for 24 hr and caspase cleavages were measured by immunoblotting 
analysis. GAPDH was used as a loading control. Prognosis and percent viable cells determined by annexin V/PI binding assay for each 
sample is provided. The ratio between the protein of interest and its respective GAPDH is set as 100%. C = untreated CLL. K.-M. 
Correlation between percent apoptosis and caspase cleavage (caspases 8, 9 and 3) following smac066 treatment (5 µM; 24 hr). The r2 on 
the correlation is obtained through linear regression analysis.
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Figure 4: Effect of pan-caspase inhibitor Z-VAD-fmk on smac066-induced apoptosis. A. CLL primary cells were incubated 
with smac066 (S) in the presence or absence of Z-VAD-fmk (Z), and percent viable cells was determined by annexin/PI binding assay (n 
= 12). The given p values are derived from paired t-test analyzed using Graph Pad Prizm. The horizontal lines denote median values. C = 
untreated CLL. B.-C. Protein levels of IAPs (XIAP, cIAP1, and cIAP2) and Bcl-2 family anti-apoptotic proteins (Bcl-2, Mcl-1, and Bcl-
xL) were determined by immunoblotting. Pt 67a-d denotes that this patient arrived twice to the clinic and the immunoblot analyses were 
done twice. GAPDH was used as a loading control. D. Mouse embryo fibroblasts for wild-type (WT) or double-knockout (DKO) Bax/Bak 
were incubated without or with various concentrations of smac066 for 24 hr (n = 3). Percent viable cells were determined by annexin/PI 
binding assay (n = 3; error bars denote mean ± SEM), and percent growth inhibition was determined by the cell counting method (n = 3; 
one representative data is produced). The data are expressed as percent relative to control (untreated cells). DMSO = dimethyl sulfoxide.
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probed for caspase-3 antibody demonstrated association of 
caspase-3 with XIAP. Treatment with smac066 resulted in 
comparatively lower levels of XIAP (in input, as well as IP 
samples) and decrease in caspase 3 that is bound to XIAP 
(compare lane 5 and 6) and an increase in Smac levels 
(compare lanes 5 and 6). These data suggest that XIAP 
and caspase-3 are in physical association with each other 
and smac066 dissociates this protein – protein interaction 
in CLL lymphocytes, and displaces caspases for activation 
(Figure 5). 
Induction of IAPs in bone marrow or lymph node 
microenvironment
A growing body of evidence suggests that the 
resistance of CLL cells to apoptosis is mediated partly 
by interactions between leukemia cells and adjacent 
stromal cells residing in the lymphatic tissue or bone 
marrow microenvironment. In order to test if smac066 
can overcome stromal-cell-mediated resistance to 
apoptosis, primary CLL cells were co-cultured with 
NKTert stromal cells that mimic the bone marrow stromal 
microenvironment, in the presence or absence of smac066. 
Smac066-induced apoptosis was partly but significantly 
abrogated in the presence of stroma (Figure 6A; n=33; 
p<0.0001). Similar results were obtained with nurse-like 
cells, which mimic the lymph node microenvironment 
(Figure 6B; n=11, p=0.0008). In order to understand the 
mechanism involved in stromal-cell-mediated resistance 
to apoptosis, IAPs were measured in CLL cells co-
cultured with stromal cells. XIAP and cIAP2 levels were 
significantly induced in cells co-cultured with stromal cells 
than in control cells (Figure 6C; n=6). Caspase-3 cleavage 
was also diminished in CLL cells co-cultured with 
stromal cells [31]. Addition of smac066 did not abrogate 
the induction of IAPs (Figure 6D; n=3) or inhibition 
of caspase activation (Figure 6E; n=3). This finding is 
consistent with the report that the resistance of CLL cells 
to Smac mimetics is due to recurrence of cIAP2 in the 
lymph node microenvironment, which inhibits formation 
of the ripoptosome complex and apoptosis [32].
Smac066 in combination with ABT-737 enhances 
apoptosis 
Smac066 is not a chemotherapeutic agent, but 
a sensitizer of apoptosis. Based on this notion, we 
hypothesized that smac066 should synergize with agents 
that prime the malignant cells to apoptosis. Because IAP 
family proteins as well as anti-apoptotic proteins are 
Figure 5: Caspase-3 associates with XIAP and smac066 disrupts the protein-protein interaction. CLL primary cells were 
incubated without or with (5 µM; 24 hr) smac066 (S). First two lanes are inputs containing 10% whole cell lysate. Cell extracts of untreated 
(C) and smac066 (S) treated were immune-precipitated (IP) for none (lane 3), mouse IgG (lane 4), mouse XIAP (lane 5) and mouse XIAP 
(lane 6) and immuno-blotted (IB) for XIAP, full-length caspase 3 (FL- C3), cIAP2, Smac, and GADPH. Immunoprecipitating XIAP also 
detected full length caspase-3 demonstrating the physical association between these two molecules. Treatment with smac066 (S) compared 
to untreated CLL (C) diminished the XIAP protein that is associated with caspase 3 (lane 6). Other proteins such as cIAP2 and GAPDH that 
were present in input were not detected in IP samples. 
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primarily responsible for resistance mechanisms in CLL, 
inhibiting both these family proteins jointly should exhibit 
synergy and enhance apoptosis. Based on this rationale, 
non-cytotoxic concentrations of smac066 (3 µM) and 
ABT-737 (3 nM) were added to CLL cells (Figure 7A; 
n=7). In comparison to apoptosis exhibited by single 
agents, the combination enhanced apoptosis (p=0.0007). 
To further explore the mechanism involved in the 
synergistic actions, both IAP family and Bcl-2 family anti-
apoptotic protein were evaluated in these samples. XIAP 
and cIAP2 protein levels in the combination samples 
demonstrated a significant reduction compared to single 
agents per se suggesting that there might be an association 
between these two family proteins (n=7; lane 4 for each 
patient sample) and their inhibition could cause double 
insult on these cells. Interestingly, Mcl-1 levels (lane 
4) and Bcl-XL (data not shown) also went down in the 
combination suggesting that there must be a relevant cross 
talk in the regulatory mechanisms of these two families of 
pro-survival proteins (Figure 7B). Additional experiments 
for caspase activation demonstrated significant decrease 
in the uncleaved fragments of caspases-8 and 9, in 
comparison to single agent smac066 or ABT-737 (Figure 
7C). 
DISCUSSION
CLL is characterized by defective apoptosis, and 
every effort to eradicate leukemic cells involves activation 
of the apoptotic switch. Molecular studies have revealed 
that protein-protein interactions between anti-apoptotic 
and pro-apoptotic proteins are partly responsible for 
resistance to apoptosis. This finding provided the rationale 
for identifying compounds such as BH3 mimetics (ABT-
737 and ABT-199) that could mimic the BH3 domain of 
pro-apoptotic proteins of the Bcl-2 family [33]. Proof of 
this principle demonstrated success in both preclinical and 
clinical investigations. Similarly, synthetic Smac mimetics 
reactivate apoptosis in tumor cells by antagonizing 
IAP family proteins. They act to facilitate apoptosis 
through one of three mechanisms. Firstly, involves their 
competitive binding to caspases and antagonizing IAPs. 
Secondly, involves autoubiquitylation and proteasomal 
degradation of cIAPs via promotion of E3 ligase activity, 
leading to RING domain dimerization and concurrent 
degradation [34], [35]. This mechanism modulates the 
activity of nuclear factor κB, with consequent stimulation 
of TNFα, which in turn promotes formation of a receptor-
interacting serine-threonine-protein kinase 1 (RIPK1)-
dependent caspase-8-activating complex, leading to 
activation of caspases 3, 7 and 8 [36]. Thirdly, involves 
activation of the cell’s extrinsic apoptotic pathway by 
autocrine TNFα stimulation or the presence of TNF or 
TRAIL in the tumor microenvironment. Compared with 
Smac peptides, small-molecule mimetics have superior 
affinity for IAPs, cell permeability, in vivo stability, and 
oral activity. 
The Smac mimetic, smac066, used in the present 
study, induces apoptosis as a single agent (Figure 2) by 
promoting degradation of IAPs in primary CLL cells 
(Figure 3C-3E). However, Z-VAD-fmk experiments 
revealed that smac066 is a specific antagonist of IAPs 
but not Mcl-1, as Z-VAD-fmk reversed caspase-mediated 
cleavage of Mcl-1 but not IAP proteins (Figure 4B and 
4C). There was a strong association between apoptosis, 
IAP degradation and concurrent caspase activation 
(Figures 2 & 3). 
Full-length XIAP is known to directly inhibit 
caspases 3, 7, and 9; cIAP1 inhibits caspases 3 and 7; 
and cIAP2 inhibits caspases 3, 7, and 9. XIAP, cIAP1, 
and cIAP2 do not inhibit caspases 1, 6 and 8[37, 38]. 
In our studies, although smac066 is synthesized to bind 
to BIR3 domains of IAPs, [24] which are required for 
inhibition of caspase-9, it concurrently induced activation 
of caspases-8 and 3. It is possible that both activation 
of caspase-9 or degradation of cIAP1/2 and concurrent 
activation of caspase-8 [12] converge in a common 
pathway that ultimately leads to apoptosis by inducing the 
“executioner” caspases, caspase-3 and -7. Furthermore, 
active caspase-8 may cleave the pro-apoptotic BH3 
only protein Bid to truncated Bid (tBID) which can 
translocate into the mitochondria, triggering activation of 
the intrinsic pathway that leads to cytochrome c release 
and apoptosome formation and ultimately to activation of 
caspases-9 and 3. Of note, Smac mimetic has been shown 
to overcome apoptosis resistance in caspase 8-deficient 
cells by priming TNFα to induce caspase-independent 
necroptosis or sensitizing apoptosis-proficient cells to 
TNFα-mediated caspase-dependent apoptosis [39]. 
A growing body of evidence indicates that there is 
a fatal attraction between leukemia cells and the “feeder 
cells” that reside in the compartments of lymph nodes and 
the bone marrow. These feeder cells, called nurse-like cells 
or stromal cells, support leukemic cells with nutrients and 
drug resistance signals. In the present study, two model 
systems that mimic the bone marrow and lymph node 
microenvironments respectively, showed enhanced cell 
survival (Figure 6A-6B). In addition, smac066-induced 
apoptosis was partially abrogated by stromal co-cultures 
(Figure 6A-6B). We previously demonstrated that Mcl-
1 protein was induced in the presence of stroma, and 
this induction was partially responsible for enhanced 
chemoresistance [40]. In this study both XIAP and cIAP2 
proteins were significantly induced in co-cultured cells. 
In the same line, caspase cleavage was diminished. 
The induction of IAPs with stroma co-cultures was not 
reversed by smac066 (Figure 6D; n=3; compare lane 3 and 
4 for each patient). This finding suggests that a surplus 
amount of IAPs is induced in the microenvironment, and 
as a result, smac066 is unable to balance the pro- and anti-
survival mechanisms. 
Several small-molecule mimetics (monomers or 
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Figure 6: Effect of bone marrow and lymph node microenvironments on smac066-driven apoptosis. CLL lymphocytes 
were co-cultured with NKTert stromal cells (Str) (A.; n = 33) or nurse-like cells (NLC) (B.; n = 11) in the presence or absence of smac066 
(S), (24 hr) and percent viable cells was determined by annexin/PI binding assay. The horizontal lines denote median values. The given 
p values are derived from paired t-test analyzed using Graph Pad Prizm. The horizontal lines denote median values. C = untreated CLL. 
C. Primary CLL cells were co-cultured with NKtert stromal cells, and the samples were evaluated for IAPs (XIAP and cIAP2) and anti-
apoptotic proteins Bcl-2 and Mcl-1. D.-E. CLL cells were incubated with NKtert stromal cells in the presence or absence of smac066, and 
expression of IAPs (XIAP and cIAP2), anti-apoptotic protein Mcl-1, and apoptosis marker poly(ADP-ribose) polymerase as well as caspase 
cleavages (caspases 8, 9, and 3) were evaluated by immunoblotting (n = 3). GAPDH was used as a loading control.
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dimers) are in development for treatment of hematological 
malignancies [17, 41] and solid tumors [42-46]. 
Birinapant, a bivalent Smac mimetic with high affinity for 
IAPs, acts through degradation of cIAP1 and caspase-8 
activation in acute myeloid leukemia [41]. Birinapant is 
currently used in the clinic for patients with lymphoma or 
solid tumors, alone and in combination with other agents 
[47, 48]. A phase I/II clinical trial of Birinapant as a single 
agent is launched for elderly patients with AML. LCL161, 
GDC-0917, HGS1029, and AT-406 are other agents that 
are currently being evaluated in phase I studies, alone or 
in combinations, for patients with advanced malignancies. 
Figure 7: Smac066 synergize with ABT-737. A. Primary cells were incubated with smac066 in combination with ABT-737 and 
the apoptosis was measured by annexin/PI binding assay (n = 7). The given p values are derived from paired t-test analyzed using Graph 
Pad Prizm. The horizontal lines denote mean values. B. CLL primary cells were incubated with smac066 in combination with ABT-737 
and IAPs and Mcl-1 were evaluated by immunoblotting analysis (n = 7). Red -XIAP; GAPDH and Green - cIAP2 and Mcl-1. C. CLL 
primary cells were incubated with smac066 in combination with ABT-737 and uncleaved fragment of caspases-8 and 9 were evaluated by 
immunoblotting analysis (n = 3). GAPDH was used as a loading control.
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The therapeutic potential and clinical utility of these 
agents will be understood shortly with the clinical trials 
that are currently ongoing.
PATIENTS AND METHODS
Drugs and chemicals 
Smac066 for in vitro use was kindly provided by 
P. Seneci, CISI scrl, University of Milan, Italy. The final 
concentration of vehicle (DMSO; Sigma-Aldrich (St. 
Louis, MO)) in untreated and treated samples was 0.1%. 
Patients and healthy donors
This study involved lymphocytes obtained from 
healthy donors and patients with CLL. CLL or normal 
PBMCs were isolated from peripheral blood by Ficoll-
hypaque gradient method and re-suspended in 10% 
autologous plasma in RPMI media as described previously 
[49]. All patients participated in the study had signed 
written informed consent forms in accordance with the 
Declaration of Helsinki, and the laboratory protocols 
were approved by the IRB at the UT MD Anderson 
Cancer Center. All patients were included in the study 
or experiments irrespective of treatment status, age or 
prognosis. 
Marrow Stromal Cell (MSC) co-culture
For CLL-stromal co-culture studies, lymphocytes 
were incubated without or with confluent layers of 
human Marrow Stromal Cells (MSC; NKtert; RIKEN 
cell bank, Tsukuba, Japan) at the ratio of 100 CLL-cells 
to 1 MSC [49]. The NKTert cell line has been maintained 
and routinely checked for Mycoplasma infection and 
authenticated by short tandem repeat (STR) analysis at 
MD Anderson Cancer Center’s “characterized cell line 
core facility”.
Measurement of cell viability 
CLL cell viability was analyzed as described 
previously by standard methods: annexin V/propidium 
iodide (PI) binding and 3,3-dihexyloxocarbocyanine iodide 
(DiOC6) staining, based on the analysis of mitochondrial 
transmembrane potential and cell membrane permeability 
to PI [50]. 
Bax/Bak wild-type and double-knockout mouse 
embryo fibroblasts
Exponentially growing Bax/Bak wild-type or 
double-knockout cell lines (obtained from John C. Reed, 
Sanford-Burnham Medical Research Institute, San Diego, 
CA) were used for apoptosis and growth inhibition assays 
with smac066. 
Nurse-like cells
Nurse-like cell cocultures were established by 
suspending peripheral blood mononuclear cells (PBMCs) 
from patients with CLL in complete RPMI 1640 medium 
with 10% fetal bovine serum and penicillin-streptomycin-
glutamine (HyClone) to a concentration of 107 cells/mL 
(total 2 mL). The cells were monitored, and fresh medium 
was added as necessary. Cells were incubated for 2 weeks 
in 24-well plates (Corning Life Sciences) as previously 
described [51].
Immunoblot analysis
Cell pellets were lysed in RIPA lysis buffer and 
the protein content was determined using a DC protein 
assay kit (Bio-Rad Laboratories). The proteins were run 
on electrophoresis gels and transferred to nitrocellulose 
membranes (GE Osmonics Labstore) as described 
previously [50]. Membranes were blocked for 1 hr in 
blocking buffer, incubated with primary antibodies 
against XIAP (BD Biosciences, 610762; as per company, 
this antibody detects two bands and the lower band is 
specific for XIAP, as indicated by arrows in the figures); 
cIAP1 (Abcam, ab2399); cIAP2 (Epitomics, S2700; as per 
company, this antibody detects two bands and the upper 
band is specific for cIAP2, as indicated by arrows in the 
figures); Smac (BD Biosciences, 612246); caspase 3, (Cell 
Signaling, 9665) caspase 8 (Cell Signaling 9746), and 
caspase 9 (Cell Signaling, 9502); polyclonal antibody to 
Mcl-1 or Bcl-xL; and mouse monoclonal antibody to Bcl-
2 (Santa Cruz, CA) or to GAPDH (Abcam, Cambridge, 
MA).  The antibody to poly(ADP-ribose) polymerase 
was from BIOMOL International (Plymouth Meeting, 
PA). Following washing with PBST, membranes were 
incubated for 1 hr with infrared dye-labeled secondary 
antibodies (LI-COR Biosciences), scanned, and visualized 
using a LI-COR Odyssey infrared imager.
Immunoprecipitation
Protein–protein interaction between caspases and 
IAPs was analyzed by immunoprecipitation experiments. 
Protein G Immunoprecipitation Kit (Sigma-Aldrich) was 
used according to the manufacturer’s instructions.
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Statistical analysis
Linear regression analysis and paired student’s 
t-tests (two tailed) were performed by GraphPad Prism 
6 software (GraphPad Software, Inc. San Diego, CA). 
The statistical analysis for each graph and error bars 
are denoted in figure legends for the respective figures. 
Sample size, patient number and prognosis are provided 
for every experiment included. 
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